DOCSLIB.ORG

年度報告 Annual Report 2019 * 泸州银行股份有限公司 並非香港法例第155章 《銀行業條例》 所指認可機構，不受香港金融管理局的監督，亦不獲授 權在香港經營銀行╱接受存款業務。 * Luzhou Bank Co., Ltd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
年度報告 Annual Report 2019 * 泸州银行股份有限公司 並非香港法例第155章 《銀行業條例》 所指認可機構，不受香港金融管理局的監督，亦不獲授 權在香港經營銀行╱接受存款業務。 * Luzhou Bank Co., Ltd 年度報告 ANNUAL REPORT 2019 * 泸州银行股份有限公司並非香港法例第155章 《銀行業條例》 所指認可機構，不受香港金融管理局的監督，亦不獲授 權在香港經營銀行╱接受存款業務。 * Luzhou Bank Co., Ltd. is not an authorised institution within the meaning of the Banking Ordinance (Chapter 155 of the Laws of Hong Kong), not subject to the supervision of the Hong Kong Monetary Authority, and not authorised to carry on banking/deposit-taking business in Hong Kong. Contents Corporate Overview 2 Accounting Data and Financial Indicators Summary 4 Chairman’s Statement 6 President’s Statement 8 Management Discussion and Analysis 10 Changes in Share Capital and Information on Shareholders 52 Directors, Supervisors, Senior Management and Employees 58 Corporate Governance Report 80 Directors’ Report 110 Report of the Board of Supervisors 120 Important Events 124 Independent Auditor’s Report 125 Statement of Comprehensive Income 131 Statement of Financial Position 132 Statement of Changes In Equity 133 Statement of Cash Flows 134 Notes to the Financial Statements 136 Unaudited Supplementary Financial Information 253 Definitions 255 2 Luzhou Bank • ANNUAL REPORT 2019 Corporate Overview I. CORPORATE PROFILE (i) Legal Names 1. Legal Chinese name: 瀘州銀行股份有限公司 (Abbreviation in Chinese: 瀘州銀行) 2. Legal English name: LUZHOU BANK CO., LTD. (Abbreviation in English: LUZHOU BANK) (ii) Registered Capital: RMB2,264,793,385 (iii) Legal Representative: Mr. YOU Jiang (iv) Authorized Representatives: Mr. LIU Shirong, Ms. SO Shuk Yi Betty (v) Joint Company Secretaries: Mr. LIU Shirong, Ms. SO Shuk Yi Betty (vi) Listing place of H shares: The Stock Exchange of Hong Kong Limited (vii) Abbreviated Stock Name and Stock Code: LUZHOU BANK (1983.HK) (viii) Registered Address: Building 1, No. 18, Section 3, Jiucheng Avenue, Jiangyang District, Luzhou, Sichuan Province, the PRC (ix) Principal Place of Business in Hong Kong: 40th Floor, Sunlight Tower, No. 248 Queen’s Road East, Wanchai, Hong Kong (x) Contact Address: Building 1, No. 18, Section 3, Jiucheng Avenue Jiangyang District, Luzhou, Sichuan Province, the PRC Post Code: 646000 Website: www.lzccb.cn (xi) Address for Inspection of this Annual Report: Office of the Board of Directors of the Bank (xii) Auditor: International: PricewaterhouseCoopers Address: 22/F, Prince’s Building, Central, Hong Kong Domestic: PricewaterhouseCoopers Zhong Tian LLP (Special General Partnership) Address: 11/F, PricewaterhouseCoopers Center, 2 Corporate Avenue, 202 Hu Bin Road, Huangpu District, Shanghai, PRC (xiii) PRC Legal Advisor: JunHe LLP, Shanghai Office (xiv) Hong Kong Legal Advisor: King & Wood Mallesons (xv) Compliance Advisor: TC Capital International Limited (xvi) H Share Registrar and Transfer Office: Computershare Hong Kong Investor Services Limited (xvii) Registration Date: September 15, 1997 (xviii) Registration Authority: Luzhou City Administration for Industry & Commerce in Sichuan Province, the PRC (xix) Unified Social Credit Code: 91510500708926271U ANNUAL REPORt 2019 • Luzhou Bank 3 Corporate Overview (xx) Financial License Institution Number: B0210H251050001 (xxi) Customer Service and Complaints Hotline: 0830-96830 (xxii) Tel: 0830-2362606 (xxiii) Fax: 0830-3100625 (xxiv) E-mail: [email protected] II. CORPORATE INFORMATION Headquartered in Luzhou, the PRC, Luzhou Bank was established on September 15, 1997 as approved by the PBoC. The Bank has one branch in Chengdu, the PRC as well as seven primary sub-branches and 28 secondary sub-branches in Luzhou, the PRC. As at the end of the Reporting Period, our total assets amounted to RMB91,681 million; our total loans and advances to customers amounted to RMB44,759 million, and our total deposits from customers amounted to RMB61,437 million. Our H shares have been listed on the main board of Hong Kong Stock Exchange on December 17, 2018 (stock code: 1983). III. MAJOR HONORS ACHIEVED IN 2019 Study and Practice Concerning Monitoring Model for Operational Risks of Small and Medium Commercial Banks 《中小商業銀行操作風險監測模型研究與實踐》( ) was rated by the General Office of CBIRC as National Class 4 Achievement in January 2019. “Advanced Industrial Targeted Poverty Alleviation Collective (產業精準扶貧先進集體)” granted by The People’s Bank of China Chengdu Branch and Sichuan Labour Union in February 2019. One of the First 28 Commercial Banks in China to Pilot Mobile Number Payment determined by Clearing Center of PBoC in February 2019. The “Rong e Dai” Innovation Case won the “Top Ten Consumer Financial Innovation Award (十佳消費 金融創新獎)” of the 2019 China Financial Innovation Award in May 2019. “Best Financial Inclusion Award of the Year (年度最佳普惠金融獎)” granted by Sichuan Banking Association in July 2019. “2018 Advanced Unit of Financial Poverty Alleviation (2018年度金融扶貧工作先進單位)” granted by the CBIRC Sichuan Office in August 2019. We won Third Prize in the Attack and Defense Competition for Sichuan Banking Institutions in September 2019. 2nd ranking in “2018 Most Competitive City Commercial Bank with Total Assets less than RMB100 billion (2018年度資產規模1,000億元以下城市商業銀行競爭力排名第二名)” and “Best Strategic Management City Commercial Bank (最佳戰略管理城市商業銀行)” granted in the awards for Chinese most competitive commercial banks in 2019 sponsored by the Banker (銀行家) magazine in November 2019. “Best Mobile Banking Innovation Award” granted by China Financial Certification Center (CFCA) in December 2019. “2019 regional service leader bank” granted by Hexun financial bank summit in December 2019. 4 Luzhou Bank • ANNUAL REPORT 2019 Accounting Data and Financial Indicators Summary Unit: RMB’000 Year-on- Item 2019 2018 year change 2017 2016 2015 Operating results change (%) Net interest income 2,718,125 1,772,398 53.36 1,574,335 1,155,636 885,201 Net fee and commission income 5,085 1,868 172.22 (1,890) 495 2,505 Operating income 2,806,631 1,934,088 45.11 1,679,956 1,306,982 942,180 Operating expenses (1,036,331) (686,928) 50.86 (543,168) (437,427) (273,227) Expected credit losses/Impairment losses on assets (944,739) (396,810) 138.08 (324,846) (155,669) (89,136) Profit before tax 829,648 853,990 (2.85) 814,486 716,800 587,646 Net profit 633,912 658,307 (3.71) 618,703 542,084 451,475 Net profit attributable to our shareholders 633,912 658,307 (3.71) 618,703 542,084 451,475 Per share (RMB) change Net assets per share attributable to our shareholders(1) 3.04 2.92 0.12 2.65 2.77 2.53 Basic earnings per share(2) 0.28 0.40 (0.12) 0.38 0.35 0.52 Diluted earnings per share 0.28 0.40 (0.12) 0.38 0.35 0.52 Year-on- Item 2019 2018 year change 2017 2016 2015 Scale indicators (RMB’000) change (%) Total assets 91,680,621 82,549,815 11.06 70,879,436 53,280,661 31,763,629 Of which: loans and advances to customers, net(3) 43,298,734 30,486,354 42.03 18,833,833 14,159,076 9,703,381 Total liabilities 84,791,112 76,183,029 11.30 66,543,721 49,273,247 28,479,524 Of which: deposits from customers 61,436,960 52,385,604 17.28 42,145,297 31,018,756 20,383,361 Share capital 2,264,793 2,182,933 3.75 1,637,193 1,448,844 1,297,619 Equity attributable to our shareholders 6,889,509 6,366,786 8.21 4,335,715 4,007,414 3,284,105 Total equity 6,889,509 6,366,786 8.21 4,335,715 4,007,414 3,284,105 Profitability indicators (%) change Return on average total assets(4) 0.73 0.86 (0.13) 1.00 1.27 1.65 Return on average equity(5) 9.47 14.66 (5.19) 14.83 14.87 19.68 Net interest spread(6) 2.85 2.43 0.42 2.55 3.19 3.57 Net interest margin(7) 3.08 2.53 0.55 2.65 3.24 3.76 Net fee and commission income to operating income(8) 0.18 0.10 0.08 (0.11) 0.04 0.27 Cost-to-income ratio(9) 35.95 34.54 1.41 31.89 31.46 24.27 Asset quality indicators (%) change NPL ratio 0.94 0.80 0.14 0.99 0.53 0.30 Allowance coverage ratio 349.78 319.36 30.42 294.49 486.63 920.63 Allowance to gross loan ratio 3.28 2.54 0.74 2.93 2.58 2.75 ANNUAL REPORt 2019 • Luzhou Bank 5 Accounting Data and Financial Indicators Summary Year-on- Item 2019 2018 year change 2017 2016 2015 Capital adequacy indicators (%) change Core tier-one capital adequacy ratio(10) 9.31 10.69 (1.38) 10.40 12.68 17.53 Tier-one capital adequacy ratio(10) 9.31 10.69 (1.38) 10.40 12.68 17.53 Capital adequacy ratio(10) 12.09 13.29 (1.20) 13.69 13.62 18.58 Other indicators (%) change Liquidity ratio 83.72 73.40 10.32 48.42 44.99 57.72 Notes: (1) Net assets per share attributable to our shareholders = (equity attributable to our shareholders – other equity instruments)/the number of ordinary shares at the end of the period. (2) Basic earnings per share are calculated by dividing the net profit for the year/period attributable to shareholders of the Bank by the weighted average number of ordinary shares during the period. (3) Net loans and advances to customers = total loan and advances to customers – impairment allowance on loans and advances to customers. (4) Return on average total assets = net profit/the average balance of total assets at the beginning and the end of the period. (5) Return on average equity = net profit attributable to our shareholders of ordinary shares/the weighted average balance of equity attributable to our shareholders of ordinary shares at the beginning and the end of the period. (6) Net interest spread = the average yield on interest-earning assets – the average cost of interest-bearing liabilities.
Load more

Recommended publications
  • Luzhou Laojiao Co., Ltd. 2018 Annual Report April 2019
    2018 Annual Report of Luzhou Laojiao Co.,Ltd. Luzhou Laojiao Co., Ltd. 2018 Annual Report April 2019 1 2018 Annual Report of Luzhou Laojiao Co.,Ltd. Section I Important Statements, Contents and Definitions The Board of Directors, Board of Supervisors, directors, supervisors and senior management guarantee that the information presented in this report is free of any false records, misleading statements or material omissions, and shall Individually and together be legally liable for truthfulness, accuracy and completeness of its contents. Mr. Liu Miao, responsible person for the Company, Ms. Xie Hong, responsible person for accounting work and Mr. Yan Li, responsible person for the Company’s financial affairs (Accounting Supervisor) have warranted that the financial statements in this report are true and complete. Other directors attended the board meeting to deliberate this report by themselves except the following directors. Name of directors who did not Position of directors who did not Reason for not attending Name of attend the meeting in person attend the meeting in person the meeting in person deputies Liu Miao Chairman of the Board work Lin Feng Shen Caihong Director work Jiang Yuhui Affected by risks, uncertainties and assumptions, the forward-looking statements concerning business objectives and future plans made in this report based on the subjective assumptions and judgments of the future policies and economic conditions may be significantly different from the actual results. Such statements shall not be considered as virtual promises of the Company to investors, and the investors and relevant persons shall maintain adequate risk awareness and shall understand the differences between plans, forecasts and commitments.
    [Show full text]
  • Table of Codes for Each Court of Each Level
    Table of Codes for Each Court of Each Level Corresponding Type Chinese Court Region Court Name Administrative Name Code Code Area Supreme People’s Court 最高人民法院 最高法 Higher People's Court of 北京市高级人民 Beijing 京 110000 1 Beijing Municipality 法院 Municipality No. 1 Intermediate People's 北京市第一中级 京 01 2 Court of Beijing Municipality 人民法院 Shijingshan Shijingshan District People’s 北京市石景山区 京 0107 110107 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Haidian District of Haidian District People’s 北京市海淀区人 京 0108 110108 Beijing 1 Court of Beijing Municipality 民法院 Municipality Mentougou Mentougou District People’s 北京市门头沟区 京 0109 110109 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Changping Changping District People’s 北京市昌平区人 京 0114 110114 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Yanqing County People’s 延庆县人民法院 京 0229 110229 Yanqing County 1 Court No. 2 Intermediate People's 北京市第二中级 京 02 2 Court of Beijing Municipality 人民法院 Dongcheng Dongcheng District People’s 北京市东城区人 京 0101 110101 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Xicheng District Xicheng District People’s 北京市西城区人 京 0102 110102 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Fengtai District of Fengtai District People’s 北京市丰台区人 京 0106 110106 Beijing 1 Court of Beijing Municipality 民法院 Municipality 1 Fangshan District Fangshan District People’s 北京市房山区人 京 0111 110111 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Daxing District of Daxing District People’s 北京市大兴区人 京 0115
    [Show full text]
  • NPC Members of Yilong County Visited PFGHL Nanchong Factory
    NPC Members of Yilong County Visited PFGHL Nanchong Factory On the morning of July 25, 2017, the delegates participating in the second session of the 17th Yilong County People's Congress gathered to visit the construction and development of the county seat and Industrial Park of Yilong County, Nanchong City of Sichuan Province. The county government officers including Guo Zonghai, Zheng Yuanqin, Li Jun, Deng Bulin, Leng Guanjun, Xu Yuan, Wu Kaihong, Chen Zhi, and Tang Guoying joined the visit and were informed of the details regarding the county’s key project of PFGHL Nanchong Factory and Hong Kong investments. After conducting detailed inspections of the facilities, the county government officers were confident of the immense developmental potential of the PFGHL Nanchong Factory. They provided praise for the achievements of the factory and displayed encouragement for the continued progression of the project. During the visit, the Factory Manager initially briefed the government officials and delegates on the current state of PFGHL Group and its Nanchong factory, namely the PFGHL Nanchong Factory. He said, "PFGHL is one of the leading one-stop international service providers in China’s garment industry. Its factories are distributed across the Chinese mainland and Hong Kong, forming a large interconnected garment manufacturing and service network. Its products are distributed internationally in a timely manner". Subsequently, the Factory Manager focused on introducing the efforts made by the PFGHL Nanchong Factory in environmental protection. The factory is operated to be in full compliance with Yilong County’s policy of green development. It is dedicated to implementing the county’s principle of protecting the Jialing River, its water bodies, and the surrounding hills.
    [Show full text]
  • Lung-Targeting Drug Delivery System of Baicalin- Loaded
    Journal name: International Journal of Nanomedicine Article Designation: Original Research Year: 2017 Volume: 12 International Journal of Nanomedicine Dovepress Running head verso: Wei et al Running head recto: Lung-targeting drug delivery system of baicalin-loaded nanoliposomes open access to scientific and medical research DOI: http://dx.doi.org/10.2147/IJN.S119895 Open Access Full Text Article ORIGINAL RESEARCH Lung-targeting drug delivery system of baicalin- loaded nanoliposomes: development, biodistribution in rabbits, and pharmacodynamics in nude mice bearing orthotopic human lung cancer Yumeng Wei1 Abstract: The present study aims to develop a kind of novel nanoliposomes for the lung-targeting Jing Liang1 delivery system of baicalin as a Chinese medicine monomer. Baicalin-loaded nanoliposomes Xiaoli Zheng2 were prepared by the effervescent dispersion and lyophilized techniques. Baicalin-loaded Chao Pi1 nanoliposomes had an average particle size of 131.7±11.7 nm with 0.19±0.02 polydispersity Hao Liu1 index, 82.8%±1.24% entrapment efficiency and 90.47%±0.93% of yield and sustaining drug Hongru Yang3 release effect over 24 h and were stable for 12 months at least. In vitro no hemolytic activity was observed for the experimental drug concentration. After intravenous administration of Yonggen Zou4 baicalin-loaded nanoliposomes to rabbits, drug concentration in the lungs was the highest among Yun Ye1,5 the tested organs at all time points and was significantly higher than that of its solution. For the 1 Ling Zhao targeting parameters, the relative intake rate and the ratio of peak concentration of lung were 1Department of Pharmaceutics, 4.837 and 2.789, respectively.
    [Show full text]
  • Efficacy of Additional Corticosteroids to Multimodal Cocktail Periarticular
    Li et al. Journal of Orthopaedic Surgery and Research (2021) 16:200 https://doi.org/10.1186/s13018-021-02317-5 CORRECTION Open Access Correction to: Efficacy of additional corticosteroids to multimodal cocktail periarticular injection in total knee arthroplasty: a meta-analysis of randomized controlled trials Qi Li1, Guo Mu2, Xiangbo Liu3 and Milian Chen1* Correction to: J Orthop Surg Res 16, 77 (2021) https://doi.org/10.1186/s13018-020-02144-0 Following the publication of the original article [1], the authors found out mistake on the affiliation section. Reference They did not find this error during proofreading. The 1. Li Q, Mu G, Liu X, et al. Efficacy of additional corticosteroids to multimodal authors would like to apologize for this mistake. cocktail periarticular injection in total knee arthroplasty: a meta-analysis of randomized controlled trials. J Orthop Surg Res. 2021;16:77 https://doi.org/1 The order of all authors remains the same, but the 0.1186/s13018-020-02144-0. error lies on affiliations 2 and 3. The correct affiliations are shown below. These have also been updated in this article. 2 Department of Anesthesiology, Zigong Fourth People’s Hospital, NO.19 Tanmulin Street, Ziliujin, Zigong 643000, Sichuan Province, People’s Republic of China. 3 Southwest Medical University, NO.319, Section 3, Zhongshan road, Jiangyang District, Luzhou 643000, Sichuan Province, People’s Republic of China. Author details 1Department of Anesthesiology, Shehong People’s Hospital, NO.19, Guanghan road, Shehong 629200, Sichuan Province, People’s Republic of China. 2Department of Anesthesiology, Zigong Fourth People’s Hospital, NO.19 Tanmulin Street, Ziliujin, Zigong 643000, Sichuan Province, People’s Republic of China.
    [Show full text]
  • 2021033003506.Pdf
    Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. (A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 6806) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020 The board of directors (the “Board”) of Shenwan Hongyuan Group Co., Ltd. (the “Company”) hereby announces the audited results of the Company and its subsidiaries for the year ended December 31, 2020. This results announcement, containing the full text of the 2020 annual report of the Company, complies with the relevant requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited in relation to the information to accompany preliminary announcement of annual results. The Company’s annual results for the year ended December 31, 2020 have been reviewed by the audit committee of the Board. This results announcement will be published on the HKEXnews website of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the website of the Company (www.swhygh.com) respectively. The 2020 annual report will be dispatched to the H shareholders of the Company and published on the HKEXnews website of Hong Kong Exchanges and Clearing Limited and the website of the Company in due course. By Order of the Board Shenwan Hongyuan Group Co., Ltd.
    [Show full text]
  • List of Designated Supervision Sites for Imported Grain
    Firefox https://translate.googleusercontent.com/translate_f List of designated supervision sites for imported grain Serial Designated supervision Types Imported Venue (venue) Off zone mailing address Business unit name number site name of varieties customs code Tianjin Lingang Jiayue No. 5, Bohai 37 Road, Tianjin Lingang Grain and Oil Imported Lingang Economic 1 Tianjin Jiayue Grain and Oil A CNDGN02S619 Grain Designated Zone, Binhai New Terminal Co., Ltd. Supervision Site Area, Tianjin Designated Supervision No. 2750, No. 2 Road, Site for Inbound Grain Tanggu Xingang, Tianjin Port First 2 Tianjin A CNTXG020051 by Tianjin Port First Binhai New District, Port Co., Ltd. Port Co., Ltd. Tianjin Designated Supervision No. 529, Hunhe Road, Site for Inbound Grain Lingang Economic Tianjin Lingang Port 3 Tianjin A CNDGN02S620 by Tianjin Lingang Port Zone, Binhai New Group Co., Ltd. Group Area, Tianjin Designated Supervision No. 2750, No. 2 Road, Site for Inbound Grain Tanggu Xingang, Tianjin Port Fourth 4 Tianjin A CNTXG020448 of Tianjin Port No. 4 Binhai New District, Port Co., Ltd. Port Company Tianjin No. 2750, No. 2 Road, Designated Supervision Tanggu Xingang, Tianjin Port Fourth 5 Tianjin Site for Imported Grain A CNTXG020413 Binhai New District, Port Co., Ltd. in Xingang Beijiang Tianjin Tianjin Port Designated Supervision No. 6199, Donghai International Sorghum, corn, 6 Tianjin Site for Inbound Grain Road, Tanggu District, Logistics B CNTXG020051 sesame in Tianjin Port Tianjin Development Co., Ltd. Designated Supervision Central Grain No.9 Road, Haigang Site for Inbound Grain Reserve Tangshan 7 Shijiazhuang Development Zone, A CNTGS040165 at Jingtang Port Grocery Direct Depot Co., Tangshan City Terminal Ltd.
    [Show full text]
  • Report Into Allegations of Organ Harvesting of Falun Gong Practitioners in China
    REPORT INTO ALLEGATIONS OF ORGAN HARVESTING OF FALUN GONG PRACTITIONERS IN CHINA by David Matas and David Kilgour 6 July 2006 The report is also available at http://davidkilgour.ca, http://organharvestinvestigation.net or http://investigation.go.saveinter.net Table of Contents A. INTRODUCTION .............................................................................................................................................- 1 - B. WORKING METHODS ...................................................................................................................................- 1 - C. THE ALLEGATION.........................................................................................................................................- 2 - D. DIFFICULTIES OF PROOF ...........................................................................................................................- 3 - E. METHODS OF PROOF....................................................................................................................................- 4 - F. ELEMENTS OF PROOF AND DISPROOF...................................................................................................- 5 - 1) PERCEIVED THREAT .......................................................................................................................................... - 5 - 2) A POLICY OF PERSECUTION .............................................................................................................................. - 9 - 3) INCITEMENT TO HATRED ................................................................................................................................-
    [Show full text]
  • Supplemental Information Nrf1 Is Endowed with a Dominant
    Supplemental information Nrf1 is endowed with a dominant tumor-repressing effect onto the Wnt/-Catenin -dependent and -independent signaling networks in the human liver cancer Jiayu Chen1,2,§, Meng Wang1,§, Xufang Ru1,3,§, Yuancai Xiang1,4,§, Yonggang Ren1,5,§, Xiping Liu2, Lu Qiu1,6, and Yiguo Zhang1* 1The Laboratory of Cell Biochemistry and Topogenetic Regulation, College of Bioengineering and Faculty of Sciences, Chongqing University, No. 174 Shazheng Street, Shapingba District, Chongqing 400044, China. 2Department of Biochemistry and Molecular Biology, Zunyi Medical University, No. 6 Xuefu-Xi Road, Xinpu New District, Zunyi 563000, Guizhou, China. 3Department of Neurosurgery, Southwest Hospital, Army (Third Military) Medical University, No. 29 Gaotanyan Street, Shapingba District, Chongqing 400038, China. 4Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southwest Medical University, No. 1 at the First Section of Xianglin Road, Longmatan District, Luzhou 646000, Sichuan, China. 5Department of Biochemistry, North Sichuan Medical College, No. 55 Dongshun Road, Gaoping District, Nanchong 637000, Sichuan, China. 6School of Life Sciences, Zhengzhou University, No. 100 Kexue Avenue, Zhengzhou 450001, Henan, China. §Contributed equally to this work. *Correspondence should be addressed to Yiguo Zhang (Email: [email protected], or [email protected]) 1. Supplemental materials and methods 1.1 The TOPflash Luciferase reporter assay to measure β-catenin/Tcf-driven transcriptional activity. Human 293T cells (2×104) were seeded in each well of a 48-vial plate and allowed for growth to 70% confluence. The cells were co-transfected with 100 ng of the firefly luciferase reporter called TOPflash (driven by the consensus β-catenin/Tcf4-binding site) or its mutant control plasmid called FOPflash, together with 5 ng of Renilla luciferase reporter (pRL-CMV), plus 10 pmol of indicated small interference RNA targeting for Nrf1 (i.e., siNrf1) or a scrambled negative control RNA (i.e.
    [Show full text]
  • Luzhou City Commercial Bank Co., Ltd.* 瀘州市商業銀行股份有限公司* (The “Bank”) (A Joint Stock Company Incorporated in the People’S Republic of China with Limited Liability)
    The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Luzhou City Commercial Bank Co., Ltd.* 瀘州市商業銀行股份有限公司* (the “Bank”) (A joint stock company incorporated in the People’s Republic of China with limited liability) WARNING The publication of this Application Proof is required by The Stock Exchange of Hong Kong Limited (the “Exchange”)/the Securities and Futures Commission (the “Commission”) solely for the purpose of providing information to the public in Hong Kong. This Application Proof is in draft form. The information contained in it is incomplete and is subject to change which can be material. By viewing this document, you acknowledge, accept and agree with the Bank, its sponsor, advisors or members of the underwriting syndicate that: (a) this document is only for the purpose of providing information about the Bank to the public in Hong Kong and not for any other purposes. No investment decision should be based on the information contained in this document; (b) the publication of this document or supplemental, revised or replacement pages on the Exchange’s website does not give rise to any obligation of the Bank, its sponsor, advisors or members of the underwriting syndicate to proceed with an offering
    [Show full text]
  • Global Offering *
    LUZHOU XINGLU WATER XINGLU WATER LUZHOU 瀘 州 市 興 瀘 水 務 （ 集 團） 股 份有 限 公 司 ( GROUP (a joint stock company incorporated in the People’s Republic of China with limited liability) Stock Code: 2281 ) CO., LTD. GLOBAL OFFERING * Sole Sponsor and Sole Global Coordinator Joint Bookrunners and Joint Lead Managers * For identification purposes only IMPORTANT IMPORTANT: If you are in any doubt of the contents of this prospectus, you should obtain independent professional advice. Luzhou Xinglu Water (Group) Co., Ltd.* 瀘州市興瀘水務（集團）股份有限公司 (a joint stock company incorporated in the People’s Republic of China with limited liability) GLOBAL OFFERING Number of Offer Shares under the Global Offering : 214,940,000 H Shares (comprising 195,400,000 H Shares to be offered by the Company and 19,540,000 Sale Shares to be offered by the Selling Shareholders, subject to the Over-allotment Option) Number of Hong Kong Public Offer Shares : 21,494,000 H Shares (subject to adjustment) Number of International Offer Shares : 193,446,000 H Shares (comprising 173,906,000 H Shares to be offered by the Company and 19,540,000 Sale Shares to be offered by the Selling Shareholders, subject to adjustment and the Over-allotment Option) Maximum Offer Price : HK$2.53 per H Share, plus a brokerage of 1.0%, an SFC transaction levy of 0.0027% and a Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund) Nominal Value : RMB1.00 per H Share Stock Code : 2281 Sole Sponsor and Sole Global Coordinator Joint Bookrunners and Joint Lead Managers Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this prospectus, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this prospectus.
    [Show full text]
  • Luzhou Laojiao Co., Ltd. 2019 Annual Report April 2020
    2019 Annual Report of Luzhou Laojiao Co., Ltd. Luzhou Laojiao Co., Ltd. 2019 Annual Report April 2020 1 2019 Annual Report of Luzhou Laojiao Co., Ltd. Section I Important Statements, Contents and Definitions The Board of Directors, Board of Supervisors, directors, supervisors and senior management guarantee that the information presented in this report is free of any false records, misleading statements or material omissions, and shall individually and together be legally liable for truthfulness, accuracy and completeness of its contents. Mr. Liu Miao, responsible person for the Company, Ms. Xie Hong, responsible person for accounting and Ms. Yan Li, responsible person for the Company’s financial affairs (Accounting Supervisor) have warranted that the financial statements in this report are true and complete. Other directors attended the board meeting to deliberate this report by themselves except the following directors. Position of directors who Name of directors who did not Reason for not attending did not attend the meeting Name of deputies attend the meeting in person the meeting in person in person Lin Feng Director Work Liu Miao Affected by risks, uncertainties and assumptions, the forward-looking statements concerning business objectives and future plans made in this report based on the subjective assumptions and judgments of the future policies and economic conditions may be significantly different from the actual results. Such statements shall not be considered as virtual promises of the Company to investors, and the investors and relevant persons shall maintain adequate risk awareness and shall understand the differences between plans, forecasts and commitments. In the annual report, the potential risks in the operation of the Company have been disclosed.
    [Show full text]